Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

484.03 -0.80 (-0.17%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

75 76 Next >

Vertex to Acquire Crinetics Pharmaceuticals

July 06, 2026

From Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.

Via Business Wire

Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher? ↗

July 06, 2026

The pharma stock is up around 17% this year.

Via The Motley Fool

While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead ↗

July 05, 2026

This big biotech stock doesn't get the hype that SpaceX does. But it could be the smarter bet right now.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗

June 23, 2026

Via Chartmill

VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals ↗

June 01, 2026

Via Chartmill

Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout ↗

May 28, 2026

Via Chartmill

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗

July 03, 2026

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

Via The Motley Fool

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

July 01, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗

July 01, 2026

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare?

Via The Motley Fool

Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)

June 29, 2026

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. ...

Via StockStory

Topics Artificial Intelligence

$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

June 29, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on an annualized basis producing an average annual return of 19.73%. Currently, Vertex Pharmaceuticals...

Via Benzinga

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 27, 2026

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

Via The Motley Fool

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗

June 23, 2026

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

Via MarketBeat

Topics ETFs

The Best Stocks to Invest $1,000 in Right Now ↗

June 22, 2026

Exploring some of the top bargains in a multi-trillion-dollar industry.

Via The Motley Fool

3 of Wall Street’s Favorite Stocks to Consider Right Now

June 22, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

2 Reasons to Like VRTX (and 1 Not So Much)

June 22, 2026

Vertex Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $452.99. The stock also fell s...

Via StockStory

If I Had to Start Over With $1,000 in Stocks Today, Here's Exactly What I'd Buy ↗

June 20, 2026

These well-established companies are on track to deliver more growth.

Via The Motley Fool

Topics Intellectual Property

Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. ↗

June 20, 2026

These companies don't typically compete directly with one another, but that might change soon.

Via The Motley Fool

Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗

June 18, 2026

The opportunity is enormous, but uncertainty remains.

Via The Motley Fool

3 Market-Beating Stocks Worth Investigating

June 18, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Via StockStory

The Best Biotech Stocks to Buy in 2026 ↗

June 17, 2026

They have at least one thing in common: An exciting pipeline.

Via The Motley Fool

Topics ETFs

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

June 11, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗

June 08, 2026

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.

Via The Motley Fool

CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗

June 08, 2026

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

Via The Motley Fool

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

June 05, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

The Best Stocks to Invest $500 in Right Now ↗

June 04, 2026

The market is underestimating these companies' long-term prospects.

Via The Motley Fool

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

June 03, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

June 01, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges

May 29, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade...

Via StockStory

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗

May 25, 2026

Are there significant gains ahead for one (or both) of these innovative biotechs?

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.